Skip to content

Study to evaluate the effect of Shatyadi Churna and Dashmooladi Kwatha on symptoms and lung function in patients with Bronchial Asthma.

CLINICAL STUDY TO EVALUATE THE COMBINED EFFECT OF SHATYADI CHURNA AND DASHMOOLADI KWATHA IN TAMAK SHWASA (BRONCHIAL ASTHMA)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113765
Enrollment
30
Registered
2026-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J452- Mild intermittent asthma

Interventions

Intervention1: Shatyadi Churna Dashmooladi kwatha: Shatyadi Churna 3gm orally twice Daily After Meal with Dashmooladi Kwatha 80 ml as Anupana, administered twice Daily For 60 days in patients Diagnos

Sponsors

ARVIND RAJ
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patient is having classical features of Tamak Shwasa as mentioned in the classics Male or female between the age group of 18 to 60 years PEFR 100 to 300 liter per minutes

Exclusion criteria

Exclusion criteria: Patients with bronchial asthma associated with complications such as bronchitis emphysema or cor pulmonale Patients suffering from status asthmaticus Patients diagnosed with pulmonary tuberculosis lung cancer or pulmonary fibrosis Patients having a Peak Expiratory Flow Rate (PEFR) below 100 liters per minute Patients with a disease duration of more than 10 years Patients suffering from cardiac diseases such as cardiac asthma or ischemic heart disease Patients suffering from any other major medical or psychiatric disorder

Design outcomes

Primary

MeasureTime frame
Relief in subjective symptoms including Shayanah Shwasha Piditaha (breathlessness during lying position) Aasinolabhate Saukhyama (comfort in sitting posture) Shwasakrichhta (dyspnea) Ghurghurukama (wheezing sound) Parsve Avagruhyate (chest tightness)Timepoint: The assessment of the patients will be done on the 1st 20th 40th and 60th days

Secondary

MeasureTime frame
Relief in objective parameters- 1.Peak expiratory flow rate (PEFR) 2.Absolute Eosinophil Count (AEC) 3.Erythrocyte Sedimentation Rate (ESR) Timepoint: Assessment will be done on 0 day and 60 day

Countries

India

Contacts

Public ContactARVIND RAJ

UAU GURUKUL CAMPUS HARIDWAR

pandey.punita62@gmail.com9084394202

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026